Results 71 to 80 of about 1,553,849 (227)

HBV-CARE Networking Day Report.docx

open access: yes, 2023
A systematic report of the HBV-CARE (Clinicians, Advocates and Researchers Exchange) group networking day held at The Francis Crick Institute.
Marion Delphin (11921561)   +2 more
core   +1 more source

Soroprevalência de marcadores da infecção pelo HBV e dos títulos de anti-HBs em indivíduos soropositivos para o HIV [PDF]

open access: yes, 2014
Dissertação (mestrado) - Universidade Federal de Santa Catarina, Centro de Ciências de Saúde, Programa de Pós-Graduação em Farmácia, Florianópolis, 2014.As infecções pelo HIV e pelo HBV são preocupantes problemas de saúde pública, sendo que, a infecção ...
Martins, Saulo
core  

Impact of HBcrAg levels on HBsAg seroconversion after HBV rebound: a case report

open access: yesJournal of Pharmaceutical Health Care and Sciences, 2023
Background Nucleoside analogues (NAs) such as entecavir are required for at least 12 months when patients with resolved hepatitis B virus (HBV) infection develop HBV reactivation.
Maki Ohkubo   +3 more
doaj   +1 more source

Kinetics of hepatitis B virus replication in anti-HBc positive/HBsAg-negative people with HIV switching to tenofovir sparing therapy

open access: yesInternational Journal of Infectious Diseases
Objectives: To unravel the still unexplored HBV-replicative kinetics in anti-HBc-positive/HBsAg-negative people-with-HIV (PWH) suspending tenofovir disoproxil-fumarate/tenofovir-alafenamide (TDF/TAF).
Romina Salpini   +16 more
doaj   +1 more source

The association of HBV core promoter double mutations (A1762T and G1764A) with viral load differs between HBeAg positive and anti-HBe positive individuals: A longitudinal analysis [PDF]

open access: yes, 2009
Background/Aims: Although there have been a few reports regarding the effect of basal core promoter (BCP) double mutations (A1762T and G1764A) on hepatitis B viral loads, the association remains uncertain.
Fang, Kong-Xiong   +17 more
core   +1 more source

Human biomarker navigator

open access: yesiMeta, EarlyView.
The Human Biomarker Navigator integrates the disease continuum, biomarker dynamics, cross‐organ biomarker networks, biomarker classification, and technology‐driven paradigms. It maps how biomarkers link multi‐system physiology and pathology across the nervous, respiratory, endocrine, circulatory, immune, digestive, urinary, reproductive, and ...
Meng‐Yao Li   +29 more
wiley   +1 more source

Tracking the source of the hepatitis B virus-specific CD8 T cells during lamivudine treatment [PDF]

open access: yes, 2003
Lamivudine treatment in chronic hepatitis B leads to the reconstitution of virus-specific T cells in the circulation, but it is not clear whether this is the preferential result of T cell efflux from the liver or lymph nodes.
Gotto, J   +8 more
core  

The risky body mass index ranges for significant hepatitis B viral load: A campus-based study

open access: yes, 2014
Significant hepatitis B viral load (>= 10,000 copies/mL) was established to increase risk of advanced liver diseases. The aim of this study was to explore the metabolic risk factors for significant hepatitis B viral load.
Chiang, Chien-Hsieh;Lai, Jin-Shin;Sheu, Jin-Chuan;Yen, Lee-Lan;Liu, Chun-Jen;Huang, Kuo-Chin   +1 more
core   +1 more source

Decoding sequence recognition code of nucleic acid‐binding proteins of human‐infecting DNA viruses

open access: yesiMeta, EarlyView.
Human‐infecting DNA viruses remain major health threats, yet the DNA‐recognition mechanisms of their nucleic acid‐binding proteins (NBPs) are poorly understood. Here, we systematically profiled 103 viral NBPs from human‐infecting DNA viruses, with three NBPs from non‐human‐infecting DNA viruses as controls, using high‐throughput screening.
Meifang Tang   +10 more
wiley   +1 more source

Insights into Hepatitis B Virus DNA Integration-55 Years after Virus Discovery

open access: yesThe Innovation, 2020
Hepatitis B virus (HBV), which was discovered in 1965, is a threat to global public health. HBV infects human hepatocytes and leads to acute and chronic liver diseases, and there is no cure.
Kaitao Zhao, Andrew Liu, Yuchen Xia
doaj   +1 more source

Home - About - Disclaimer - Privacy